

Haematologica
HAEMATOL/2017/176859
Version 4

Bortezomib-based immunosuppression after reduced-intensity
conditioning hematopoietic stem cell transplantation: randomized phase
II results

John Koreth, Haesook T. Kim, Paulina B. Lange, Samuel J. Poryanda,
Carol G. Reynolds, Sharmila Chamling Rai, Philippe Armand, Corey S.
Cutler, Vincent T. Ho, Brett Glotzbecker, Rushdia Yusuf, Sarah
Nikiforow, Yi-Bin Chen, Bimalangshu Dey, Malgorzata McMasters,
Jerome Ritz, Bruce R. Blazar, Robert J. Soiffer, Joseph H. Antin, and
Edwin P. Alyea

Disclosures: JK: Takeda Pharmaceuticals Advisory Board, Millennium Pharmaceuticals Research funding. YBC: Millennium Pharmaceuticals Consulting, Research Funding. The study was presented in part at the American Society of Hematology Annual Meeting 2016. JK is a Scholar in Clinical Research of the Leukemia and Lymphoma Society. This study was supported in part by Millennium Pharmaceuticals Inc., the Jock and Bunny Adams Research and Education Endowment, and the National Institutes of Health CA183560, CA183559, and P01CA142106.

Contributions: Research design: JK, HTK Data: JK, PBL, SJP, CJR, SCR, PA, CSC, VTH, BG, RY, SN, YBC, BD, MM, BRB, JR, RJS, JHA, EPA Statistical analysis: HTK Manuscript writing: JK Manuscript editing and review: All authors